Cargando…
A Systematic Approach to Treating Early Metabolic Disease and Prediabetes
At least 70% of US adults have metabolic disease. However, less is done to address early disease (e.g., overweight, obesity, prediabetes) versus advanced disease (e.g., type 2 diabetes mellitus, coronary artery disease). Given the burden of advanced metabolic disease and the burgeoning pandemics of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499776/ https://www.ncbi.nlm.nih.gov/pubmed/37543535 http://dx.doi.org/10.1007/s13300-023-01455-9 |
_version_ | 1785105780895121408 |
---|---|
author | Carris, Nicholas W. Bunnell, Brian E. Mhaskar, Rahul DuCoin, Christopher G. Stern, Marilyn |
author_facet | Carris, Nicholas W. Bunnell, Brian E. Mhaskar, Rahul DuCoin, Christopher G. Stern, Marilyn |
author_sort | Carris, Nicholas W. |
collection | PubMed |
description | At least 70% of US adults have metabolic disease. However, less is done to address early disease (e.g., overweight, obesity, prediabetes) versus advanced disease (e.g., type 2 diabetes mellitus, coronary artery disease). Given the burden of advanced metabolic disease and the burgeoning pandemics of obesity and prediabetes a systematic response is required. To accomplish this, we offer several recommendations: (A) Patients with overweight, obesity, and/or prediabetes must be consistently diagnosed with these conditions in medical records to enable population health initiatives. (B) Patients with early metabolic disease should be offered in-person or virtual lifestyle interventions commensurate with the findings of the Diabetes Prevention Program. (C) Patients unable to participate in or otherwise failing lifestyle intervention must be screened to assess if they require pharmacotherapy. (D) Patients not indicated for, refusing, or failing pharmacotherapy must be screened to assess if they need bariatric surgery. (E) Regardless of treatment approach or lack of treatment, patients must be consistently screened for the progression of early metabolic disease to advanced disease to enable early control. Progression of metabolic disease from an overweight yet otherwise healthy person includes the development of prediabetes, obesity ± prediabetes, dyslipidemia, hypertension, type 2 diabetes, chronic kidney disease, coronary artery disease, and heart failure. Systematic approaches in health systems must be deployed with clear protocols and supported by streamlined technologies to manage their population’s metabolic health from early through advanced metabolic disease. Additional research is needed to identify and validate optimal system-level interventions. Future research needs to identify strategies to roll out systematic interventions for the treatment of early metabolic disease and to improve the metabolic health among the progressively younger patients being impacted by obesity and diabetes. |
format | Online Article Text |
id | pubmed-10499776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-104997762023-09-15 A Systematic Approach to Treating Early Metabolic Disease and Prediabetes Carris, Nicholas W. Bunnell, Brian E. Mhaskar, Rahul DuCoin, Christopher G. Stern, Marilyn Diabetes Ther Commentary At least 70% of US adults have metabolic disease. However, less is done to address early disease (e.g., overweight, obesity, prediabetes) versus advanced disease (e.g., type 2 diabetes mellitus, coronary artery disease). Given the burden of advanced metabolic disease and the burgeoning pandemics of obesity and prediabetes a systematic response is required. To accomplish this, we offer several recommendations: (A) Patients with overweight, obesity, and/or prediabetes must be consistently diagnosed with these conditions in medical records to enable population health initiatives. (B) Patients with early metabolic disease should be offered in-person or virtual lifestyle interventions commensurate with the findings of the Diabetes Prevention Program. (C) Patients unable to participate in or otherwise failing lifestyle intervention must be screened to assess if they require pharmacotherapy. (D) Patients not indicated for, refusing, or failing pharmacotherapy must be screened to assess if they need bariatric surgery. (E) Regardless of treatment approach or lack of treatment, patients must be consistently screened for the progression of early metabolic disease to advanced disease to enable early control. Progression of metabolic disease from an overweight yet otherwise healthy person includes the development of prediabetes, obesity ± prediabetes, dyslipidemia, hypertension, type 2 diabetes, chronic kidney disease, coronary artery disease, and heart failure. Systematic approaches in health systems must be deployed with clear protocols and supported by streamlined technologies to manage their population’s metabolic health from early through advanced metabolic disease. Additional research is needed to identify and validate optimal system-level interventions. Future research needs to identify strategies to roll out systematic interventions for the treatment of early metabolic disease and to improve the metabolic health among the progressively younger patients being impacted by obesity and diabetes. Springer Healthcare 2023-08-05 2023-10 /pmc/articles/PMC10499776/ /pubmed/37543535 http://dx.doi.org/10.1007/s13300-023-01455-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Commentary Carris, Nicholas W. Bunnell, Brian E. Mhaskar, Rahul DuCoin, Christopher G. Stern, Marilyn A Systematic Approach to Treating Early Metabolic Disease and Prediabetes |
title | A Systematic Approach to Treating Early Metabolic Disease and Prediabetes |
title_full | A Systematic Approach to Treating Early Metabolic Disease and Prediabetes |
title_fullStr | A Systematic Approach to Treating Early Metabolic Disease and Prediabetes |
title_full_unstemmed | A Systematic Approach to Treating Early Metabolic Disease and Prediabetes |
title_short | A Systematic Approach to Treating Early Metabolic Disease and Prediabetes |
title_sort | systematic approach to treating early metabolic disease and prediabetes |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499776/ https://www.ncbi.nlm.nih.gov/pubmed/37543535 http://dx.doi.org/10.1007/s13300-023-01455-9 |
work_keys_str_mv | AT carrisnicholasw asystematicapproachtotreatingearlymetabolicdiseaseandprediabetes AT bunnellbriane asystematicapproachtotreatingearlymetabolicdiseaseandprediabetes AT mhaskarrahul asystematicapproachtotreatingearlymetabolicdiseaseandprediabetes AT ducoinchristopherg asystematicapproachtotreatingearlymetabolicdiseaseandprediabetes AT sternmarilyn asystematicapproachtotreatingearlymetabolicdiseaseandprediabetes AT carrisnicholasw systematicapproachtotreatingearlymetabolicdiseaseandprediabetes AT bunnellbriane systematicapproachtotreatingearlymetabolicdiseaseandprediabetes AT mhaskarrahul systematicapproachtotreatingearlymetabolicdiseaseandprediabetes AT ducoinchristopherg systematicapproachtotreatingearlymetabolicdiseaseandprediabetes AT sternmarilyn systematicapproachtotreatingearlymetabolicdiseaseandprediabetes |